Milan, Italy

Ivano Eberini

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ivano Eberini: Innovator in Neuroprotective Compounds

Introduction

Ivano Eberini is an accomplished inventor based in Cinisello Balsamo, Italy. He is currently associated with Centro Cardiologico Monzino S.p.a. Despite having no granted patents, Eberini is actively involved in the development of innovative compounds aimed at treating neurodegenerative diseases.

Latest Patent Applications

Eberini's latest patent applications include:

1. **Compounds for Use in Progressive Multiple Sclerosis** - This invention provides compounds capable of inducing neuroprotection of damaged neurons and enhancing the remyelination potential of oligodendrocytes. The compounds were identified through pharmacological screening of a small molecule library consisting of known pharmacologically active compounds and approved drugs. The screening method is also included in the invention.

2. **GPR17-Modulating Compounds, Diagnostic and Therapeutic Uses Thereof** - This application discloses compounds that can modulate the activity of the GPR17 receptor in a highly specific manner. These compounds are useful in the treatment and diagnosis of diseases or dysfunctions involving the activation of this receptor. They can be applied for neuroprotective and reparatory purposes in conditions such as cerebral, cardiac, and renal ischemia, cerebral trauma, chronic neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), and demyelinating diseases such as multiple sclerosis.

Conclusion

Ivano Eberini is making significant contributions to the field of neuroprotection through his innovative research and patent applications. His work holds promise for advancing treatments for serious neurological conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…